Calidi Biotherapeutics reports Q4 net loss of $4.1M; files IND for CLD-201 solid tumor trial

Calidi Biotherapeutics, Inc.

2025-Q1 EPS reported -$0.18 vs consensus -$1.81 ▲ beat (+90.1%)

Q4 2024 net loss $4.1M ($0.27/share) vs $8.2M loss ($0.23/share) in Q4 2023.
Full year 2024 net loss $23.8M ($2.97/share) vs $29.2M ($17.33/share) in 2023.
Cash and restricted cash $9.8M as of Dec 31, 2024, up from $2.1M as of Dec 31, 2023.
IND filed in March 2025 for CLD-201 Phase 1 trial in solid tumors (breast, head&neck, sarcoma).
CLD-101 Phase 1 trial for high-grade glioma started recruiting at Northwestern; 14th patient treated at City of Hope.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.